Company: IMNN
Filing Date: 2025-05-19
Form Type: S-1/A
Source: 0001641172-25-011388
Chunk: 19

Company: Imunon, Inc.
Filing Date: 2025-05-19
Form: S-1/A
Chunk 19
---
 are not immediately exercisable, as their exercisability is contingent upon us obtaining Stockholder Approval. The common warrants will become exercisable on Initial Exercise Date (i.e., the date on which we file a Current Report on Form 8-K with the SEC giving public notice of Stockholder Approval) and will expire two and one-half (2.5) years after the Initial Exercise Date. We have agreed to hold a meeting to obtain Stockholder Approval as soon as practicable following the closing of this offering, but no later than sixty (60) days following the closing of this offering, and further agreed to cause an additional stockholder meeting to be held every ninety (90) days thereafter until such Stockholder Approval is obtained. We cannot assure you that we will be able to obtain requisite Stockholder Approval. In the event that we cannot obtain Stockholder Approval, the common warrants may never become exercisable. If we are unable to obtain Stockholder Approval, the common warrants will have no value.

Any market activity involving short selling or other market making activities could result in negative impact to the market price for our Common Stock.

Short selling is a method used to capitalize on an expected decline in the market price of a security and could depress the price of our Common Stock, which could further increase the potential for future short sales. While the securities purchase agreement contains a prohibition against short sales between the date the offering closes and the Adjustment Date, in the event the stockholders purchasing in this offering directly or indirectly undertake any short selling, it is likely that any such sales activities would negatively impact the market price of our Common Stock. In addition, the sale of our Common Stock could also encourage short sales by market participants, which could create negative market momentum. Continued short selling may bring about a temporary, or possibly long term, decline in the market price of our Common Stock. The Company cannot predict the size of future issuances or sales of Common Stock or the effect, if any, that future issuances and sales of Common Stock will have on its market price or the activities of short sellers. Sales involving significant amounts of Common Stock, including issuances made in the ordinary course of the Company’s business, or the perception that such sales could occur, may materially and adversely affect prevailing market prices of the Common Stock.

Management will have broad discretion as to the use of the proceeds from the offering and uses may not improve our financial condition or market value.

Because we have not designated the amount of net proceeds from the offering to be used for any particular purpose, our management